literature

SARS_CoV_2 mutation literature information.

Epidemiology of COVID-19: An updated review.

PMID: 34759999 2021 Journal of research in medical sciences

Table: T716I

CRISPR-Cas12a-Based Detection for the Major SARS-CoV-2 Variants of Concern.

PMID: 34787487 2021 Microbiology spectrum

Method: The SARS-CoV-2 target sequences include (i) the wild-type (WT) gene fragment of S protein (S; nucleotides [nt] 21,563 to 25,384; GenBank accession number MN908947); (ii) the mutant gene fragments of S protein, including mutations L5F, D80A, D215G, R246I, K417N, L452R/Q, Y453F, T478K, E484Q/K, N501Y, A570D, D614G, P681H, A701V, T716I,

SARS-CoV-2 Delta (B.1.617.2) Variant: A Unique T478K Mutation in Receptor Binding Motif (RBM) of Spike Gene.

PMID: 34796036 2021 Immune network

Table: T716I

Mutation-Induced Long-Range Allosteric Interactions in the Spike Protein Determine the Infectivity of SARS-CoV-2 Emerging Variants.

PMID: 34805715 2021 ACS omega

Table: T716I

A rigorous framework for detecting SARS-CoV-2 spike protein mutational ensemble from genomic and structural features.

PMID: 34806033 2021 Current research in structural biology

Result: Eight prominent mutations were present in the first group with more than 50% frequency; N501Y, P681H, T716I, D1118H, A570D, S982A, HV69/70del, and Y144del.

The alpha/B.1.1.7 SARS-CoV-2 variant exhibits significantly higher affinity for ACE-2 and requires lower inoculation doses to cause disease in K18-hACE2 mice.

PMID: 34821555 2021 eLife

Method: The B.1.1.7 differs from the B.1 in the spike protein on positions S:N501Y, S:A570D, S:T716I, S:P681H, S:S982A, S:D1118H, S:del69/70, and S:del144/145.

Local occurrence and fast spread of B.1.1.7 lineage: A glimpse into Friuli Venezia Giulia.

PMID: 34905574 2021 PloS one

Result: Indeed, all of the SARS-CoV-2 B.1.1.7 genomes analyzed in our cohort contained all the so-called signature mutations in the Spike glycoprotein, including p.H69-V70del, p.Y144del, p.N501Y, p.A570D, p.P681H, p.T716I, p.S982A, and p.D1118H.

Hotspot Mutations in SARS-CoV-2.

PMID: 34912372 2021 Frontiers in genetics

Table: T716I

Heterologous prime-boost immunizations with chimpanzee adenoviral vectors elicit potent and protective immunity against SARS-CoV-2 infection.

PMID: 34923570 2021 Cell discovery

Method: pS-B.1.1.7 and pS-B.1.351 plasmids were constructed with mutant S genes expressing the spike protein of the B.1.1.7 variant (GenBank: QQH18545.1, containing the H69, V70, and Y145 deletions and N501Y, A570D, D614G, P681H, T716I, S982A, and D1118H mutations) and B.1.351 variant (GenBank: QRI43207.1, containing the L242, A243, and L244 deletions and L18F, D80A, D215G, S305T, K417N, E484K, N501Y, D614G

Glycan Masking of Epitopes in the NTD and RBD of the Spike Protein Elicits Broadly Neutralizing Antibodies Against SARS-CoV-2 Variants.

PMID: 34925381 2021 Frontiers in immunology

Introduction: The Alpha (B.1.1.7) variant encodes an S protein with nine mutations (del 69-70, Del 144, N501Y, A570D, D614G, P681H, T716I, S982A, and D1118H), of which N501Y is in the receptor-binding domain (RBD).

Browser Board

Co-occurred Entities

Filtrator